Geron (GERN) Change in Account Payables (2025 - 2026)

Geron recorded quarterly Change in Account Payables of $1.5 million in Q1 2026, up 359.86% quarter-over-quarter from -$563000.0 in Q1 2025, and up 359.86% year-over-year from $318141.8 in Q1 2025.

Geron's Change in Account Payables history runs 2 years deep, the most recent figure standing at $1.5 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -3.26 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 35.60 Mn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn -
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -
10 Geron 846,759.37 846,759.37 - 1.46 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.46 Mn
Mar 31, 2026 1.46 Mn
Mar 31, 2025 -563,000.00
Mar 31, 2025 -563,000.00